Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
| ▸ | GJB2 | P29033 | 1/20 | 0.48 |
| ▸ | TACR2 | P21452 | 3/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.46 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.46 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.46 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.46 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.44 |
| ▸ | CDC25B | P30305 | 6/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12128006 | 1.00 | HTR1A (0.50) | HTR1ANT5EGJB2TACR2PDE4D | |
| SCHEMBL9009836 | 1.00 | HTR1A (0.50) | HTR1ANT5EGJB2TACR2PDE4D | |
| SCHEMBL7774640 | 1.00 | HTR1A (0.50) | HTR1ANT5EGJB2TACR2PDE4D | |
| SCHEMBL7774644 | 1.00 | HTR1A (0.50) | HTR1ANT5EGJB2TACR2PDE4D | |
| SCHEMBL13430417 | 0.96 | GJB2 (0.52) | HTR1ANT5EGJB2TACR2PDE4D | |
| SCHEMBL10778287 | 0.96 | GJB2 (0.52) | HTR1ANT5EGJB2TACR2PDE4D | |
| SCHEMBL10778279 | 0.96 | GJB2 (0.52) | HTR1ANT5EGJB2TACR2PDE4D | |
| SCHEMBL5473075 | 0.96 | GJB2 (0.52) | HTR1ANT5EGJB2TACR2PDE4D | |
| SCHEMBL13430414 | 0.96 | GJB2 (0.52) | HTR1ANT5EGJB2TACR2PDE4D | |
| SCHEMBL5473070 | 0.96 | GJB2 (0.52) | HTR1ANT5EGJB2TACR2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493498-B2 | Oligosaccharide-protein conjugates | GENZYME CORPORATION (US) | 2016-11-15 | — | — | US | claimed |
| US-20150175643-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION | 2015-06-25 | — | — | US | claimed |
| US-8835614-B2 | Oligosaccharide-protein conjugates | GENZYME CORPORATION (US) | 2014-09-16 | — | — | US | claimed |
| EP-2465542-A1 | Oligosaccharide-protein conjugates | Genzyme Corporation (US) | 2012-06-20 | — | — | EP | claimed |
| US-20110300120-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION | 2011-12-08 | — | — | US | claimed |
| EP-4212541-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES AND THEIR INTERMEDIATES | Genzyme Corporation (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20220242899-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION | 2022-08-04 | — | — | US | disclosed |
| US-11279725-B2 | Oligosaccharide-protein conjugates | GENZYME CORPORATION (US) | 2022-03-22 | — | — | US | disclosed |
| US-20200216485-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION | 2020-07-09 | — | — | US | disclosed |
| EP-3608330-A2 | SYNTHETIC INTERMEDIATES FOR PREPARING OLIGOSACCHARIDE-PROTEIN CONJUGATES | Genzyme Corporation (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10464962-B2 | Oligosaccharide-protein conjugates | GENZYME CORPORATION (US) | 2019-11-05 | — | — | US | disclosed |
| EP-3350192-B1 | MULTI-FUNCTIONALIZED POLYSACCHARIDE COMPOUNDS AND USE THEREOF FOR TARGETING THE CATION-INDEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR | NANOMEDSYN (FR) | 2019-08-07 | — | — | EP | disclosed |
| US-8835614-B2 | Oligosaccharide-protein conjugates | GENZYME CORPORATION (US) | 2014-09-16 | — | — | US | disclosed |
| EP-2465542-A1 | Oligosaccharide-protein conjugates | Genzyme Corporation (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20110300120-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION | 2011-12-08 | — | — | US | disclosed |
| EP-2376123-A2 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | Genzyme Corporation (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010075010-A2 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20030232978-A1 | Reagents that facilitate the purification of compounds synthesized on a solid support | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2003-12-18 | — | — | US | disclosed |
| EP-0739349-B1 | POLYMER-SUPPORTED SOLUTION SYNTHESIS OF OLIGOSACCHARIDES | INNOVATIONS FOUNDATION (CA) | 2000-05-17 | — | — | EP | disclosed |
| US-5616698-A | Polymer-supported solution synthesis of oligosaccharides | UNIVERSITY OF TORONTO INNOVATIONS FOUNDATION (CA) | 1997-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242899-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | MAN2B1, GAA, GBA1 | HTR1A 4612/4885NT5E 2722/4885GJB2 4400/4885 |
| US-20200216485-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | MAN2B1, GAA, GBA1 | HTR1A 4612/4885NT5E 2722/4885GJB2 4400/4885 |
| US-20110300120-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | MAN2B1, GAA, GBA1 | HTR1A 4612/4885NT5E 2722/4885GJB2 4400/4885 |
| US-20150175643-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | MAN2B1, GAA, GBA1 | HTR1A 4612/4885NT5E 2722/4885GJB2 4400/4885 |
| US-10464962-B2 | Oligosaccharide-protein conjugates | MAN2B1, GAA, GBA1 | HTR1A 4612/4885NT5E 2722/4885GJB2 4400/4885 |
| US-11279725-B2 | Oligosaccharide-protein conjugates | MAN2B1, GAA, GBA1 | HTR1A 4612/4885NT5E 2722/4885GJB2 4400/4885 |
| US-20030232978-A1 | Reagents that facilitate the purification of compounds synthesized on a solid support | RNGTT, CAPG, CAPRIN1 | HTR1A 3644/4885NT5E 1072/4885GJB2 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.